HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical trials roundup in idiopathic inflammatory myopathies.

AbstractPURPOSE OF REVIEW:
To review recent advances in the treatment of idiopathic inflammatory myopathies (IIMs) with emphasis on new biological agents and on some less commonly used immunosuppressive drugs.
RECENT FINDINGS:
Double-blinded comparison of oral high-dose pulse dexamethasone with standard high daily prednisolone doses showed similar efficacy in the composite score, significantly longer median time to relapse with prednisolone and fewer side effects with dexamethasone treatment. Use of intravenous immunoglobulins (IVIGs) in IIMs is associated with variable results; however, recent retrospective evaluation of IVIGs administration to steroid-resistant patients with esophageal involvement showed good effect. Whereas smaller open studies with rituximab reported a very good efficacy, even in notoriously difficult-to-treat anti-signal recognition particle-positive cases, the double-blind trial has not reached the primary endpoint. Studies with TNF neutralization are reporting results ranging from only a modest or no effect to a promising outcome in the most recent trial with etanercept. Pilot studies suggest efficacy of alemtuzumab in inclusion body myositis and allogeneic mesenchymal stem cell transplantation in polymyositis/dermatomyositis.
SUMMARY:
Unmet need for efficacious therapy in IIMs exists and therefore a coordinated effort is necessary to properly evaluate various new classical and biological agents.
AuthorsHeřman F Mann, Jiří Vencovský
JournalCurrent opinion in rheumatology (Curr Opin Rheumatol) Vol. 23 Issue 6 Pg. 605-11 (Nov 2011) ISSN: 1531-6963 [Electronic] United States
PMID21926626 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm
  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Tumor Necrosis Factor-alpha
  • Alemtuzumab
  • Rituximab
  • tocilizumab
Topics
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antibodies, Neoplasm (therapeutic use)
  • Clinical Trials as Topic
  • Dermatomyositis (therapy)
  • Glucocorticoids (therapeutic use)
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Immunosuppressive Agents (therapeutic use)
  • Interleukin 1 Receptor Antagonist Protein (therapeutic use)
  • Mesenchymal Stem Cell Transplantation
  • Myositis (therapy)
  • Rituximab
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: